IMNN (Imunon, Inc.) סך נכסי הפעילות העסקית

Imunon, Inc. (IMNN) brings together leading specialists in genetics and oncology, attracting talent with a cutting-edge foundation for immunotherapeutic research. The company's development of anti-cancer drugs is not subject to market cycles or seasonality, demonstrating resilience to crises. Growth is supported by the success of plasmid platform tests, while cash reserves stand at 11.90. This chart of the company's total asset quotes is provided below.

For Imunon, Inc. (IMNN), the growth of all company resources reflects the efficiency of capital management given the total reliance on external contract research and manufacturing organizations (CRO/CMO). This metric, calculated inversely via ROA, measures the total volume of controlled assets, allowing investors to assess the financial stability of a biotech startup lacking its own facilities and the risks of liquidity freezes at extreme metric values.